drugset / Trial / NCT00153881
Docetaxel and Carboplatin Followed by Oral Capecitabine, Docetaxel and Radiation for Esophageal Cancer
Phase 1
Completed
44 enrolled
Dartmouth-Hitchcock Medical Center
Hoffmann-La Roche · collabSanofi · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective is to determine the maximum tolerated dose of oral capecitabine, in combination with fixed doses of weekly docetaxel, and concurrent thoracic radiation for the treatment of patients with clinical stage II-III cancer of the esophagus and gastroesophageal junction.
Timeline
- Start
- 2000-02
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Background | Carboplatin | Small molecule | — | — |
| Background | Docetaxel | Small molecule | 15 mg/m2 | — |